Genomma Lab Internacional Announces Results for the Third Quarter 2024

MEXICO CITY, Oct. 23, 2024 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV:LAB) ("Genomma" or "the Company"), today announced its results for the second quarter of 2024. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise mentioned.

Comments from Genomma's CEO, Marco Sparvieri

"Genomma delivered a strong third quarter, with a 15.9% Net Sales increase, an 82% EPS increase to Ps. 0.66, and EBITDA margin expanding to 23.7% for the quarter; a 245 basis-point increase driven by our productivity initiatives' continued progress. Lower CAPEX coupled with an increased EBITDA margin resulted in a record-high free cash flow of Ps. 2.4 billion for the trailing twelve months, reflecting a 68% increase. We saw steady growth in Genomma's key markets and brands, and will continue to strengthen our core brands while we focus on achieving Ps. 1.8 billion in annual cost savings by 2027."

Q3 2024 Financial Summary

The following table provides a summary of the Company's Income Statement, in millions of Mexican pesos.

Q3 2024

% sales

Q3 2023

% sales

% var

Net Sales

5,092.5

100.0 %

4,393.2

100.0 %

+15.9 %

Like-for-like Sales(1)

+5.6 %

Gross Profit